The Experts below are selected from a list of 2313 Experts worldwide ranked by ideXlab platform
Joao A C Lima - One of the best experts on this subject based on the ideXlab platform.
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
Atul R Chugh - One of the best experts on this subject based on the ideXlab platform.
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
A L Clark - One of the best experts on this subject based on the ideXlab platform.
-
blind Atrial pacing for patients with sinus node disease who develop Atrial fibrillation during permanent pacemaker implantation
International Journal of Cardiology, 1997Co-Authors: T Fyfe, P D Macintyre, J F Robinson, A L ClarkAbstract:During a 6-year period, six of 110 patients implanted with AAI pacemakers for sick sinus syndrome developed Atrial fibrillation at the time of pacemaker implantation (5.5%). In all cases a passive fixation lead was sited in the Right Atrial Appendage, its stability being ensured by rotation of the lead and phrenic nerve stimulation excluded by pacing at 10 V. One patient remained in chronic Atrial fibrillation. In the other five, who subsequently reverted to sinus rhythm, Atrial P-wave sensing and lead threshold values were satisfactory, allowing programming of the pacemaker output down to 2.5 V to conserve the battery. One out of these five patients continued to have intermittent Atrial fibrillation. We conclude that in sick sinus syndrome, Atrial fibrillation complicates AAI pacemaker implantation procedure in 5.5% of cases. As an alternative to an unplanned general anaesthetic to cardiovert the patient, it is reasonable to implant an Atrial lead in the Right Atrial Appendage in the expectation of a spontaneous reversion to sinus rhythm with a good lead threshold and P-wave sensing. In contrast to inappropriate pacing of the Right ventricle in VVI mode, this strategy avoids pacemaker syndrome and reduces the risk of subsequent attacks of Atrial fibrillation.
Karlheinz Kuck - One of the best experts on this subject based on the ideXlab platform.
-
focal Atrial tachycardia originating from the Right Atrial Appendage first successful cryoballoon isolation
Journal of Cardiovascular Electrophysiology, 2009Co-Authors: Kr Julian Chun, Feifan Ouyang, Boris Schmidt, Karlheinz KuckAbstract:Electrical Isolation of the Right Atrial Appendage Using the Cryoballoon. Focal Atrial tachycardias (AT) can arise from the Right Atrial Appendage (RAA). However, conventional catheter mapping and radiofrequency (RF) ablation inside the RAA is associated with the risk of cardiac perforation. The cryoballoon catheter represents a novel ablation device that was originally developed to facilitate pulmonary vein isolation. This report describes the first successful RAA isolation using a cryoballoon in a patient with an incessant focal RAA AT despite previous irrigated tip endo- and epicardial ablation attempts. Further, cryoballoon ablation targets beyond pulmonary veins may evolve. (J Cardiovasc Electrophysiol, Vol. 20, pp. 338-341, March 2009)
Antone Tatooles - One of the best experts on this subject based on the ideXlab platform.
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
-
administration of cardiac stem cells in patients with ischemic cardiomyopathy the scipio trial surgical aspects and interim analysis of myocardial function and viability by magnetic resonance
Circulation, 2012Co-Authors: Atul R Chugh, Garth M Beache, John Loughran, Nathan Mewton, Julius B Elmore, Jan Kajstura, Patroklos S Pappas, Antone Tatooles, Marcus F Stoddard, Joao A C LimaAbstract:Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results. Methods and Results—A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the Right Atrial Appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5±1.6% to 35.1±2.4% [P=0.004, n=8] and 41.2±4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: −6.9±1.5 g [−22.7%] at 4 months [P...
